Structure of the Mr 140,000 growth hormone-dependent insulin-like growth factor binding protein complex: determination by reconstitution and affinity-labeling
about
Inhibition of insulin receptor activation by insulin-like growth factor binding proteinsSynthesis and characterization of insulin-like growth factor-binding protein (IGFBP)-7. Recombinant human mac25 protein specifically binds IGF-I and -IIDwarfism and impaired gut development in insulin-like growth factor II mRNA-binding protein 1-deficient miceInactivation of the acid labile subunit gene in mice results in mild retardation of postnatal growth despite profound disruptions in the circulating insulin-like growth factor systemUnderstanding the Key to Targeting the IGF Axis in Cancer: A Biomarker AssessmentIGF binding proteins in cancer: mechanistic and clinical insightsStructural determinants of ligand and cell surface binding of insulin-like growth factor-binding protein-3Mecasermin rinfabate: rhIGF-I/rhIGFBP-3 complex: iPLEXInsulin-like growth factor-binding protein 5 complexes with the acid-labile subunit. Role of the carboxyl-terminal domainInvestigational agents for the treatment of growth hormone-insensitivity syndromeInsulin-like growth factor-binding protein 5 (Igfbp5) compromises survival, growth, muscle development, and fertility in miceBinding sites and binding properties of binary and ternary complexes of insulin-like growth factor-II (IGF-II), IGF-binding protein-3, and acid-labile subunitEffect of acute elevation of IGF-I on circulating GH, TSH, insulin, IGF-II and IGFBP-3 levels in non-endocrine short stature (NESS).The complexity of the IGF1 gene splicing, posttranslational modification and bioactivityPharmacomimetics of exercise: novel approaches for hippocampally-targeted neuroprotective agents.Correlation of Circulating Acid-Labile Subunit Levels with Insulin Sensitivity and Serum LDL Cholesterol in Patients with Type 2 Diabetes: Findings from a Prospective Study with RosiglitazoneModulation of the somatotropic axis in periparturient dairy cows.Enhancement of the anabolic effects of growth hormone and insulin-like growth factor I by use of both agents simultaneously.The insulin-like growth factor system: basic and clinical aspects.Differential effects of insulin-like growth factor I and growth hormone on developmental stages of rat growth plate chondrocytes in vivo.In vivo proteolysis of serum insulin-like growth factor (IGF) binding protein-3 results in increased availability of IGF to target cellsComparison of the effects of growth hormone and insulin-like growth factor I on substrate oxidation and on insulin sensitivity in growth hormone-deficient humans.Intravenously injected insulin-like growth factor (IGF) I/IGF binding protein-3 complex exerts insulin-like effects in hypophysectomized, but not in normal rats.Regulation of binding proteins for insulin-like growth factors (IGF) in humans. Increased expression of IGF binding protein 2 during IGF I treatment of healthy adults and in patients with extrapancreatic tumor hypoglycemia.Unbound (bioavailable) IGF1 enhances somatic growth.Reduced levels of growth hormone, insulin-like growth factor-I and binding protein-3 in patients with shunted hydrocephalus.Failure of IGF-I and IGFBP-3 to diagnose growth hormone insufficiency.Serum "big insulin-like growth factor II" from patients with tumor hypoglycemia lacks normal E-domain O-linked glycosylation, a possible determinant of normal propeptide processing.Insulinlike growth factors in human malignancy.Serum complexes of insulin-like growth factor-1 modulate skeletal integrity and carbohydrate metabolismSerum IGF-1 is insufficient to restore skeletal size in the total absence of the growth hormone receptor.Bioactivity of glomerular ultrafiltrate during heavy proteinuria may contribute to renal tubulo-interstitial lesions: evidence for a role for insulin-like growth factor I.Impaired glucose homeostasis in insulin-like growth factor binding protein-1 transgenic mice.Insulin-like growth factor binding protein 3 accumulates to high levels in culture medium of senescent and quiescent human fibroblasts.Role of N- and C-terminal residues of insulin-like growth factor (IGF)-binding protein-3 in regulating IGF complex formation and receptor activation.Insulin-like Growth Factor Binding Protein-3 expression in the human corneal epithelium.The insulin-like growth factor-I/binding protein axis: physiology, pathophysiology and therapeutic manipulation.Acid-labile subunit deficiency and growth failure: description of two novel casesThe role of the insulin-like growth factor system in neuronal rescue.Expression of insulin-like growth factor-I in transgenic mice.
P2860
Q24310591-414CE893-CD80-4D24-A54E-0555A93030F6Q24322395-A2BE8FDE-C2CF-4B7C-9DD6-4E86809ACE96Q24567609-A9294C98-5BD3-4BFB-B3A6-118444660948Q24681712-00B0ED4D-C6BD-4401-A144-E8D9FAA12857Q26798408-9F4056D8-EA5F-4F42-819C-811037B970A7Q28237971-70A72C8B-BE0F-43DE-8507-E66C462921FEQ28260189-D17237D4-2FFA-487F-925B-78B6A393BC9CQ28273812-CEE7ED33-70E0-45A2-8940-6A473425432DQ28286453-F96CCF27-4CCE-44EB-8CC3-E78F9CFACDF4Q28302932-4D29E3BB-0BC0-4D16-A950-361155623F23Q28512324-DD0FB3DD-DC68-46FC-BC65-D2A5C0344F11Q28568281-5B2BE656-0DBF-4AB3-A6EF-1266FEC9BE31Q32066576-11B07BDF-F1D5-44F3-B7F1-7E029CAFAD6FQ33619027-D7F1C9F5-BB3B-45AC-B0E7-3F210349A152Q33652095-D52FABCC-40B0-47AF-9D9E-D913D7E3FF6EQ33748524-76AFCBE1-3BEE-4222-8DC7-72A6607EE4ABQ33885456-71C475C2-1D85-4647-BAF1-53720BFF43CFQ33888618-3B0A0AF4-9CCF-4D2C-936F-29B5BAEB5288Q33951247-CA237600-B239-4083-83AF-B36CEC109D2FQ34131991-9354B24F-7AB6-4734-8EFD-71366C2F7C08Q34147682-A557A92C-61D9-4F30-BC74-C50BFB0D04BDQ34184378-C2925FAA-8FD1-4D64-B240-48020CF9E858Q34194165-6BBD2E9F-0C12-4CE7-BD1C-F105FCB857D9Q34260846-F86C51C4-E3F7-4D8B-99A4-7FF2672B4D64Q35232634-C57A8B93-80E3-4F13-88DC-006253E8C390Q35255932-20479757-44A8-47B6-8659-BCB38FF5E3C4Q35263119-AC35D857-87A3-457D-8891-0D1D6B6CF660Q36377719-C7CCBDD4-0B9B-46E6-91D3-F6E4D0DB697AQ36418856-9FCC148E-AC8F-43E0-909F-5E661E0CC29AQ37123969-5F8D1E03-147B-4E22-87A3-4227A8F1CAAAQ37349402-93C74A83-2D32-415F-8383-E83B67B57CFBQ37357088-D9A0B35F-F187-4979-B70A-574FECF56228Q37360786-F18767E9-6EBA-46CD-A2A1-EC5A7353AC7BQ37612032-0AD6D247-6185-4519-A063-8FACBDD3342DQ38335404-EB7F29BB-23A0-4D44-B644-05CC5292BB53Q40091510-A280C435-42B4-4EE7-8645-2CE48D77B790Q40492402-6C448A3C-4489-4593-918B-CED5C7108702Q40507173-3B54AFB9-3639-45B4-A672-A123B55AB1DAQ40768874-92A2AF1E-C1EB-4A27-9D4C-F167E6E166C9Q40768879-BB9888C0-A9A5-4521-A976-11733B17B99B
P2860
Structure of the Mr 140,000 growth hormone-dependent insulin-like growth factor binding protein complex: determination by reconstitution and affinity-labeling
description
1989 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1989 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
article publié dans les Procee ...... f the United States of America
@fr
artículu científicu espublizáu en 1989
@ast
im September 1989 veröffentlichter wissenschaftlicher Artikel
@de
scientific journal article
@en
vedecký článok (publikovaný 1989/09/01)
@sk
vědecký článek publikovaný v roce 1989
@cs
wetenschappelijk artikel (gepubliceerd op 1989/09/01)
@nl
наукова стаття, опублікована у вересні 1989
@uk
name
Structure of the Mr 140,000 gr ...... titution and affinity-labeling
@ast
Structure of the Mr 140,000 gr ...... titution and affinity-labeling
@en
Structure of the Mr 140,000 gr ...... titution and affinity-labeling
@nl
type
label
Structure of the Mr 140,000 gr ...... titution and affinity-labeling
@ast
Structure of the Mr 140,000 gr ...... titution and affinity-labeling
@en
Structure of the Mr 140,000 gr ...... titution and affinity-labeling
@nl
prefLabel
Structure of the Mr 140,000 gr ...... titution and affinity-labeling
@ast
Structure of the Mr 140,000 gr ...... titution and affinity-labeling
@en
Structure of the Mr 140,000 gr ...... titution and affinity-labeling
@nl
P2860
P356
P1476
Structure of the Mr 140,000 gr ...... titution and affinity-labeling
@en
P2093
J L Martin
P2860
P304
P356
10.1073/PNAS.86.18.6898
P407
P577
1989-09-01T00:00:00Z